Across the medical device industry, generative AI has quietly moved from “interesting experiment” to “part of the workflow.” Engineers are using it to scaffold code and draft unit tests. ML teams are using it to explore architectures, summarize literature, and speed up documentation. Quality teams are using it to draft SOPs, triage complaints, and prep for audits. None of this happened because of a company-wide rollout; it happened because the tools are good, free or cheap to try, and one browser tab away.
That’s the upside, and it’s real. The question most organizations haven’t answered yet is what happens when that same tooling touches a regulated process.
Used well, these tools compress hours of drafting and searching into minutes. That’s a legitimate competitive advantage — and it’s exactly why adoption is accelerating faster than most quality systems were built to handle.
The same qualities that make generative AI useful — fluency, speed, willingness to produce a confident-sounding answer — are the qualities that create risk inside a regulated environment. A few considerations that don’t show up in most “AI at work” conversations:
The tool itself is unvalidated software. If an AI tool’s output feeds into a design control record, a test case, a risk assessment, or a QMS document that supports a regulatory submission, the tool is now part of your process — and your process needs evidence that it behaves reliably. This is the essence of non-product software validation: the AI assistant didn’t ship in your device, but if it shaped a deliverable that did, it needs its own layer of scrutiny.
Confident isn’t the same as correct. Generative models can produce plausible-sounding test cases, citations, or risk rationales that are subtly or completely wrong. In a QMS context, an unverified hallucination doesn’t stay contained — it can propagate into a DHF, a CAPA, or a submission.
Traceability and accountability don’t disappear because AI was involved. Under IEC 62304, ISO 14971, and ISO 13485 expectations, someone accountable still has to own the decision. “The AI suggested it” is not a design rationale, and audit trails need to show a human closed the loop.
Data governance matters before the prompt is even sent. Pasting proprietary requirements, unreleased design data, or patient-adjacent information into a public AI tool can create IP and privacy exposure that has nothing to do with the output quality.
Not every use case is a fit. Some tasks — drafting, summarizing, exploring — tolerate AI assistance well because a human reviews the output before it matters. Others, particularly anything approaching autonomous decision-making in design or risk activities, need much stricter boundaries or shouldn’t involve AI output directly at all.
None of this is a reason to avoid generative AI. It’s a reason to govern it the way you’d govern any other tool that touches a regulated deliverable.
Across the organizations doing this well, the same handful of principles keep showing up:
Controllable — usage is scoped, not open-ended
Verifiable — outputs are checked against a defined standard before they’re trusted
Traceable — there’s a record of what the AI produced and what a human did with it
Accountable — a named person owns the final decision, always
Monitorable — usage and performance are reviewed over time, not just approved once
These aren’t abstract ideals — they’re the difference between “we tried ChatGPT for test cases” and “we can show an auditor exactly how AI-assisted outputs entered our quality system, who reviewed them, and how we know they’re reliable.”